Louise Frederika Kooij Sells 75,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 75,117 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at approximately $543,150. This represents a 83.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock traded down $0.25 during trading on Monday, reaching $35.02. 372,987 shares of the company’s stock were exchanged, compared to its average volume of 944,760. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of -17.08 and a beta of 0.05. The company’s 50-day moving average is $37.08 and its two-hundred day moving average is $29.03.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. Analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. grew its stake in NewAmsterdam Pharma by 3.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after purchasing an additional 490,656 shares in the last quarter. RA Capital Management L.P. raised its stake in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company’s stock valued at $207,544,000 after buying an additional 1,293,938 shares in the last quarter. Capital World Investors lifted its holdings in NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the last quarter. Jennison Associates LLC lifted its holdings in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after buying an additional 1,252,451 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after acquiring an additional 697,129 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NAMS. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Stifel Nicolaus lifted their price target on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. The Goldman Sachs Group raised their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. Finally, HC Wainwright assumed coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They set a “buy” rating and a $52.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.90.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.